Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.62 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.61 |
| ▸ | PARP1 | P09874 | 4/20 | 0.61 |
| ▸ | TNKS | O95271 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29831694 | 1.00 | MAOB (0.62) | MAOBTNKS2PARP1TNKSHPGD | |
| SCHEMBL17153738 | 0.85 | MAOB (0.66) | MAOBTNKS2PARP1TNKSHPGD | |
| SCHEMBL9663373 | 0.82 | MAOB (0.62) | MAOBTNKS2PARP1TNKSHPGD | |
| SCHEMBL5107543 | 0.81 | MAOB (0.70) | MAOBTNKS2PARP1TNKSHPGD | |
| SCHEMBL290937 | 0.80 | KDM4E (0.46) | MAOBTNKS2PARP1HPGDALDH1A1 | |
| SCHEMBL27397831 | 0.79 | MAPK1 (0.70) | MAOBTNKS2PARP1TNKSHPGD | |
| SCHEMBL6695759 | 0.79 | TNKS2 (0.81) | TNKS2PARP1TNKSHPGDALDH1A1 | |
| SCHEMBL26694443 | 0.78 | KDM4C (0.55) | PARP1HPGDALDH1A1MAPTKMT2A | |
| SCHEMBL1396244 | 0.78 | TUBB4A (0.52) | TNKS2PARP1TNKSHPGDALDH1A1 | |
| SCHEMBL25204007 | 0.77 | ALDH1A1 (0.58) | MAOBTNKS2TNKSHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | claimed |
| EP-2130823-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2009-12-09 | — | — | EP | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| US-20240307394-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-19 | — | — | US | disclosed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
| EP-4275752-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230150929-A1 | SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 | UNIV TEXAS (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150929-A1 | SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 | UNIV TEXAS (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION | 2023-04-13 | — | — | US | disclosed |
| CN-115192711-A | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2022-10-18 | — | — | CN | disclosed |
| US-5064833-A | Substituted quinazoline derivatives for use in gastrointestinal diseases | SMITHKLINE BEECHAM INTERCREDIT B.V. (GB) | 1991-11-12 | — | — | US | disclosed |
| EP-0322133-B1 | QUINAZOLINE DERIVATIVES | SmithKline Beecham Intercredit B.V. (NL) | 1991-05-22 | — | — | EP | disclosed |
| US-4962110-A | Cardiac stimulants | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-10-09 | — | — | US | disclosed |
| EP-0322133-A1 | Quinazoline derivatives | SmithKline Beecham Intercredit B.V. (NL) | 1989-06-28 | — | — | EP | disclosed |
| WO-1989005297-A1 | COMPOUNDS | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1989-06-15 | — | — | WO | disclosed |
| US-4758557-A | Cephalosporin derivatives and bactericides containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| US-4644000-A | FUNGICIDES, BACTERICIDES, SLIMICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1987-02-17 | — | — | US | disclosed |
| EP-0209751-A2 | Cephalosporin derivatives and bactericides containing the same | MEIJI SEIKA KAISHA LTD. (JP) | 1987-01-28 | — | — | EP | disclosed |
| EP-0161418-A1 | Antimicrobial agents containing 2-(1H-pyrazol-1-yl)-4-(3H)-quinazolinones | BAYER AG (DE) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150929-A1 | SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 | CREB1, RAPGEF4, ATF4 | MAOB 4404/4885TNKS2 627/4885PARP1 2991/4885 |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | MAOB 1027/4885TNKS2 1385/4885PARP1 475/4885 |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | PDE7B, PDE4C, PDE4A | MAOB 54/4885TNKS2 2677/4885PARP1 2681/4885 |
| US-20240307394-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | MRGPRX1, MRGPRX4, MRGPRX2 | MAOB 3016/4885TNKS2 4774/4885PARP1 4563/4885 |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | PDE4B, PDE7B, PDE12 | MAOB 200/4885TNKS2 1065/4885PARP1 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.